Abstract
More than 60% of type 2 diabetes (T2D) patients in USA treated with insulin do not reach recommended HbA1c goals and a titration period can last for years. Connected devices and dose guidance tools are emerging to support this patient group in reaching better outcomes. We aim to develop a dose response model of long acting insulin to glucose dynamics to support emerging digital health and dose guidance solutions.
We perform a clinical study to collect continuous glucose monitoring (CGM) data during a long acting insulin titration period. We use the high frequency glucose data and insulin data to create a dose response model of each individual. The aim is to identify a suitable model structure of fasting glucose to long acting insulin dynamics.
The clinical study is a single centre, one arm exploratory feasibility study. We include insulin naïve adults with T2D. All patients are equipped with a smartphone, a BG meter, and a CGM during the trial period of up to 12 weeks. The primary endpoint of the study is how well a linear dose response model, given two weeks of data, can predict the dose needed to reach a target glucose level, evaluated at the end of study. We observe that a dose response model at two weeks can adequately describe the fasting glucose response at a later stage in treatment intensification.
We perform a clinical study to collect continuous glucose monitoring (CGM) data during a long acting insulin titration period. We use the high frequency glucose data and insulin data to create a dose response model of each individual. The aim is to identify a suitable model structure of fasting glucose to long acting insulin dynamics.
The clinical study is a single centre, one arm exploratory feasibility study. We include insulin naïve adults with T2D. All patients are equipped with a smartphone, a BG meter, and a CGM during the trial period of up to 12 weeks. The primary endpoint of the study is how well a linear dose response model, given two weeks of data, can predict the dose needed to reach a target glucose level, evaluated at the end of study. We observe that a dose response model at two weeks can adequately describe the fasting glucose response at a later stage in treatment intensification.
| Original language | English |
|---|---|
| Journal | Diabetes Technology & Therapeutics |
| Volume | 21 |
| Issue number | S1 |
| Pages (from-to) | A70-A70 |
| ISSN | 1520-9156 |
| DOIs | |
| Publication status | Published - 2019 |
| Event | 12th International Conference on Advanced Technologies & Treatments for Diabetes - CityCube Berlin, Berlin, Germany Duration: 20 Feb 2019 → 23 Feb 2019 Conference number: 12 |
Conference
| Conference | 12th International Conference on Advanced Technologies & Treatments for Diabetes |
|---|---|
| Number | 12 |
| Location | CityCube Berlin |
| Country/Territory | Germany |
| City | Berlin |
| Period | 20/02/2019 → 23/02/2019 |
